Abstract
Diabetes is turning into a chronicle disease with further improved drugs and more facilitated delivery systems coming out. An essential part of the drugs is insulin and its analogs that patients with diabetes use to control their blood glucose levels. The conventional treatments, like injection and open-loop (release are not responsive) transdermal delivery, are short of maintaining glucose levels in the expected range incurring risks of hypoglycemia. Nevertheless, closed-loop drug delivery shows high potential as its release response to glucose levels dynamically. In the transdermal delivery field, microneedle (MN)-array patch systems presented great capability in transdermal delivery and manipulation. So, the glucose-responsive MN-array patches that make progress in safety and convenience were drawing worldwide focus. This review provides an overview of the topic and presents some advanced outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
